Systemic lupus erythematosus (SLE) is a multisystem disease in which defects of both B and T cell function have been identified. One of the main features of immunologic abnormalities is B cell hyperactivity leading to the production of large amounts of Ig and various kinds of autoantibodies (Blaese et al. 1980; Smith and Steinberg 1983) . Recently, evidence has been accumulated to show that the growth of B cells and their differentiation into antibody producing cells require several soluble factors. Three factors regulating the B cell response have been reported in the human ; interleukin-4 (IL-4) for the early activation of resting B cells (Noma et al. 1986 ; Yokota et al. 1986 ), IL-5 for the growth of activated B cells , and IL-6 for the final differentiation of B cells into antibody producing cells (Hirano et al. 1985 (Hirano et al. , 1986 . It has been reported that cardiac myxoma patients showed autoimmune symptoms, hypergammaglobulinemia, and autoantibody production which could be mediated by a large amount of IL-6 released from myxoma .
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These results suggest that abnomal production of IL-6 in vitro may induce polyclonal B cell activation and autoantibody production. The abnormal excretion of IL-6 may contribute to the generalized autoimmune disease such as SLE. From these standpoints, the production of IL-6 and the immunoglobulin secretion by SLE PBMC (peripheral blood mononuclear cell) were studied.
PATIENTS AND METHODS
Patients. Blood samples were obtained from 12 women and 4 men with SLE (6 active and 10 inactive) and 13 normal healthy volunteers matched for age and sex. All patients met with more than four of the revised American Rheumatism Association criteria (Tan et al. 1982) for the diagnosis of SLE. Their age (mean+s.D.) was 35.3+years (range . At the time of study, 8 patients were under corticosteroid treatment of low dose (prednisolone 5-15 mg/day), 6 patients intermediate-dose (prednisolone 16-30 mg/day) and two patients received no corticosteroids. No patients received immunosuppresants. In two patients the study was repeated twice and in one patient the study was repeated 3 times.
Cell separation. PBMC were isolated from freshly drawn heparinized peripheral blood of patients with SLE or of healty normal volunteers (normal controls) by using a lymphocyte separation medium (Lymphoprep Nycomed AS, Oslo, Norway). The collected cells were washed twice with phosphate buffered saline (PBS) pH 7.4 and were resuspended at a concentration of 1 x 106/ml in RPMI-1640 (Nissuiseiyaku Co., Tokyo) containing 10% fetal calf serum (Gibco Laboratories, Grand Island, NY, USA), 50 U/ml penicillin, and 50 pg/ml streptomycin (Meiji Co., Tokyo) (culture medium). These PBMC were cultured at 3TC in a humidified air with 5% CO2.
T and B cell separation. PBMC were incubated in plastic culture dishes (Falcon 3002 ; Falcon Plastics, Oxnard, CA, USA) at 37°C for 2 hr under 5% CO2. After incubation, nonadherent cells were removed by three cycles of washing with PBS. The recoverd cells were poured into a nylon wool straw column (approximately 19.5 cm long and 6 mm in diameter) and incubated at 37°C for 30 min. The nonadherent T cells were collected by pouring 10 ml of warm (37°C) media to pass through the column and B rich-adherent cells were collected by pouring 5 ml of media to the column and by gentle squeezing of the straw. These procedure was repeated twice. The recoverd cells were used as purified T cells and B cells, respectively. Purified T cells contained more than 92% of CD5-positive cells and purified B cells contained more than 95% of CD19-positive cells.
Assay of 3 H-thymidine incorporation into PBMC. PBMC (lx 105) were cultured in 0.1 ml culture medium in flat-bottomed microtiter culture plates (Nunclon 167008; Nundon, Roskilde, Denmark) with or without 0.125 ,ug/ml of PWM (pokeweed mitogen ; Gibco Laboratories) at 37°C. For the assay of tritiated thymidine ([3H] TdR specific activity of 5Ci/mM ; Amersham Buckinghamshire, England, UK) incorporation into the cells, the cells were pulsed with 0.5 ,u Ci of 3H-TdR on day 1 or day 5 and were harvested on day 2 or day 6, respectively, with the aid of an automated cell harvester (Labo Sciense Co., Tokyo). The radioactivity incorporated into PBMC was measured with a betacounten (LSC-1000, Alloka, tokyo) (Harrison et al. 1974) . The data were expressed as mean and SE values of cpm in triplicate culture.
Analysis of secreted IgG and IgM. An ELISA was used to determine IgG and IgM concentrations in culture supernatants. Polystyrene microtiter plates (Dynatec Laboratories Inc., Alexander, VA, USA) were coated with a affinity-purified goat anti-human IgG or IgM antibody (y-chain specific or ,u-chain specific ; Cappel Laboratories, Malvern, PA, USA) in carbonate-bicarbonate buffer pH 9.6. After an overnight incubation at 3TC, the plates were washed with PBS containing Tween 20 and incubated with serial dilutions of standard IgG, IgM or culture supernatant for 2 hr at 3TC. The washed plates were then incubated with alkaline phosphatase conjugated affinity purified goat anti-human IgG or IgM antibody (TAGO Inc., Burlingham, CA, USA) for 1 hr at 3TC. After addition of the substrate, the developed color was quantitated with an ELISA reader (Bio-Rad 2550; Bio-Red, Richmond, CA, USA ). The amounts of IgG or IgM in the supernatants were determined from the standard curve of purified IgG or IgM.
For measurement of anti-single-stranded DNA antibodies (anti-ss DNA ab) in culture supernatant, the MESA ss DNA-G test (MBL, Nagoya) were used.
Assay of IL-6 activity. IL-6 dependent hybridoma cells, MH-60 BSF2, which were donated by Drs. T. Hirano and T. Kishimoto, Osaka University, Osaka, were used. Ten thousand cells were mixed with 0.1 ml of PBMC culture supernatants or a serial dilution of standard human recombinant IL-6 (hIL-6) for 48 hr and pulsed with [3H] TdR for the last 16 hr (Muraguchi et al. 1981 . The IL-6 activities in the culture supernatants were expressed as equivalent amounts of hIL-6 required for the same biologic activities.
Culture of PBMC. PBMC (1 X 106/ml) were cultured with various kinds of stimulants such as phytohemagglutinine (PHA ; 1,ug/ml ; Sigma Chemical Co., St. Louis, MO, USA), 12-0-tetradecanoyl phorbol-l3-acetate (TPA ; 5 ,u g/ml ; Sigma Chemical Co. ), &a-phylococcus aureus Cowan I (SAC ; 0.002%, supplied by Dr. S. Sawada, Nihon University, Tokyo) or lipopolysaccharide (LPS ; 10,ug/ml ; Sigma Chemical Co.) for 3 days at 37°C and the obtained supernatants were assayed for IL-6 activity and IgG and IgM synthesis.
Analysis of peripheral blood lymphocytes by 2-dimentional flow cytometry. 
RESULTS
Laboratory data of peripheral blood from SLE patients tested in the present study. As shown in Table 1 (a), serum levels of y-globulin, IgG, IgM were almost within normal ranges. Complement levels were decreased and titers of anti-ss DNA antibody increased remarkably compared to the normal values.
CD4+ and CD8+ cells, their subsets and CD19+ cells in PBMC. The percentage of CD4+, CD4+Leu8+, CD4+Leu8-, CD4+HLA-DR + , CD19+, CD8+, CD8+ CDllb+, CD8+CDllb-and CD8+HLA-DR + cells in PBMC was compared between SLE patients and normal controls (Table ib) . The percentages of CD4+HLA-DR+, CD8+, CD8+CDllb-and CD8+HLA-DR + cells were significantly high (p < 0.01) and that of CD4+ was low in SLE patients.
Serum levels of IL-6. IL-6 levels was detected in almost all serum samples tested (Table 1(c) ). However, serum IL-6 levels were considerably lower in SLE patients (1.09 + 0.16) than those in normal controls (1.42 + 0.17) (p <0.05).
3H-TdR-incorporation into PBMC . Three samples each of PBMC (5x 105/ well) from patients with SLE and normal controls were cultured for one day.
Ten samples of SLE PBMC and 6 samples of control PBMC were cultured for 5 days. The samples were incubated in vitro with or without PWM. The radio-activity of PBMC and stimulation index of PWM were shown in Table 2 . In one day culture without PWM, SLE PBMC showed a higher thymidine uptake (1859± 667.5) than that in controls (389.6± 156). In one day culture with PWM, however, the thymidine uptake of SLE PBMC (2842.3+0) was similar to that of control PBMC (2895.0+443). In 5 day culture without PWM, radioactivity of SLE PBMC (12198) was less than that of control PBMC (26003) and similar activities of 58148 and 56672 were obtained by PWM stimulation in SLE and controls, respectively. Levels of IgG, IgM and IL-6 synthetized by PBMC from SLE patients and normal controls. PBMC (5 x 105/well) from SLE patients or normal controls were cultured with or without PWM, and the amounts of Ig and IL-6 produced were assayed on day 5. The kinetics of Ig production by PBMC was surveyed (date not shown) and it was confirmed that the peak of the Ig levels for both IgG and IgM was obtained on the 5th day of culture. As shown in Table 3 , synthesis of IgG by normal PBMC was enhanced to 160.7+ 154.7 by PWM stimulation from Neverthless, the stimulation of SLE PBMC by PWM did not enhance IgG synthesis (198.2 + 103). The levels of IgM synthesis of SLE PBMC were not so different from those of normal PBMC without stimulation. However, the increase of IgM synthesis in SLE by PWM stimulation was less than those in normals. IL-6 levels were significantly (p <0.05) higher with PWM stimulation than without stimulation in SLE patients but not so in normal controls. No significant difference was observed in IL-6 levels between SLE patients and normal controls in both with and without PWM stimulation.
Levels of IL-6 synthesized by PBMC of 7 normal controls, 7 SLE patients with or without stimulation of PHA+TPA, SAC or LPS were shown in Fig. 1 . IL-6 levels in PBMC cultures from normal controls increased slightly upon stimulation with PHA plus TPA and with SAC, whereas IL-6 levels in those from SLE patients did not increase with any stimuli. No significant difference in IL-6 levels was observed between normal and SLE patients. Then, T and B cells were separated from PBMC, and IL-6 levels synthetized by either T or B cells were Fig, 1 . Levels of IL-6 synthetized by PBMC (1 x 106/ml) in 7 SLE patients and in 7 normal controls with and without stimuli of PHA (1,u g/ml), TPA (12-0-tetradecanoyl-phorbol-l3-aoetate, 5 1u g/ml ), SAC (0.002%) or LPS (10 ,ug/ml). NS, no stimulation. Table 4 , no significant difference in IL-6 levels was observed between T or B of SLE and T or B of normal controls with or without stimulation with mitogens. Correlation between laboratory data of peripheral blood and the data obtained from in vitro studies of PBMC. In SLE patients, correlation among serum levels of y-globulin, IgG, IgM, and complements, percentage of lymphocyte subsets in PBMC, stimulation index of PBMC by PWM, amount of IgG, IgM, anti-ssDNA antibody synthetized by PBMC cultured for 5 days and IL-6 synthetized by TABLE 5. Correlation between levels of serum proteins (A), lymphocyte subsets (B) or data of the cultured PBMC (C) and levels of IL-6 synthetized by PBMC of patients with SLE PBMC were studied. As seen in Table 5 , there were no correlations between the levels of IL-6 synthetized by PBMC and the levels of IgG, IgM both in serum and cultured supernatants.
IL-6 levels synthetized by T cells or B cells of PBMC in SLE patients
Significantly inverse correlation was noticed only between percentage of CD19+ cells in PBMC and IL-6 synthetized by PBMC (p < 0.02). The correlation between IL-6 levels synthetized by PBMC and percentage (a) or numbers (b) of CD19+ cells was demonstrated in Fig. 2 .
Finally, PBMC (1 X 105/well) from 5 SLE patients and 5 normal controls were cultured for 5 days in a presence of various concentrations of IL-6 ranging from 0.1 to 1,000 U/ml and IgG levels in culture supernatant was measured. The augmentation of IgG synthesis from PBMC by IL-6 was expressed by a divided value of IgG synthetized with IL-6 by IgG synthetized without IL-6. As shown in Fig. 3 , no significant difference was observed between the values of SLE patient and normal controls in various concentrations of IL-6.
DISCUSSION
In the present study, I analyzed the mechanism of hypergammaglobulinemia of SLE patients mainly from the standpoints of the synthesis of IL-6 and Ig serection in culture supernatants of SLE PBMC and the response of SLE PBMC to IL-6. IL-6 could augment the production of IgG and IgM in PWM-stimulated PBMC ) and induces final maturation of B cells into antibody producing cells (Muraguchi et al. 1981; Hirano et al. 1985 ; Takatuki et al. 1988). The PBMC of SLE patients showed enhanced proliferation on day one culture without stimulation. Higher Ig production was detected in SLE patients by in vitro culture without stimulation than in normal controls. Then, I compared between the levels of IL-6 synthetized spontaneously and those synthetized on rvitogen stimulation by PBMC of SLE patients and normal controls. There were no difference between levels of IL-6 synthetized spontaneously and those synthetized on stimulation by PBMC from any of the different groups tested. Also, there was no difference in response to IL-6 between PBMC of SLE patients and those of normal controls. Several authors presented data on the production of IL-6 and responce PBMC in SLE to the BCGF and BCDF. Hirose et al. (1985) reported that BCGF production was either normal or reduced in SLE compared to those in controls. There was an early increased production of BCDF by lupus T cells reported in patients with both active and inactive disease (Hirose et al. 1985) . Cordero et al. (1986) found an increased production of both BCGF and BCDF and increased response to BCGF of PBMC in SLE receiving no corticosteroid or immunosuppresive drugs. On the other hand, Richard (1988) reported that neither spontaneous nor mitogen-induced BCDF production is enhanced in PBMC of either active or inactive SLE. The difference in these reports might be a difference in the methods used to assay IL-6. Hirose et al. (1985) used isolated normal B cells preactivated with Staphylococcus aureus cowan 1 rvitogen to assay supernatants from PHA stimulated T cells, whereas Cordero et al. (1986) and Richard (1988) used a BCDF responsive cell line CESS in a cellular interleukine assay. In the present study, IL-6 dependent hybridoma cells, MH-60 BSF2 were used. In addition, the clinical status of the patient in terms of disease activity and medication may contribute to the different results in levels of IL-6 synthetized. Therefore, I studied the relationship of the IL-6 activity in culture supernatants to the several clinical data in serum and data measured in culture supernatants.
There were no significant difference in the levels of IL-6 synthetized in culture supernatant and the complements in serum and the levels of immunoglobulin measured in serum and in culture supernatants.
Since IL-6 is synthetized by various cells, such as T cells, B cells and monocytes (Horii et al. 1988 ), I examined which group of cells produce more IL-6 and analyzed the relationship between the lymphocyte subsets and the levels of IL-6 produced in the culture supernatant.
There were no subset specificity in production of IL-6 in SLE patients. Percentages of T cell subsets between SLE patients and the controls were significantly different, which was consistent with the results reported by other investigators (Morimoto et al. 1987; Sato et al. 1987 ). However, there were no relationships between these T cell subsets and the levels of IL-6. Contrarily to T lymphocyte subset, there was no difference in the percentage of CD19+ cells between the normal controls and SLE patients. However, there was a significant inverse correlation between the percentage or absolute numbers of CD19+ cells and the levels of IL-6 produced. Several authors (Fauci and . 1987) . So, under a speculation that activated B cells in vivo will respond to the higher level of IL-6 and will synthetize the higher level of IgG, I examined the IL-6 levels in SLE and normal sera. High levels of IL-6 were not detected in sera of SLE patients nor in culure supernatants of PBMC of SLE patients, and no correlation between the levels of IL-6 and the higher level of Ig in SLE sera was also detected.
These results suggested that B cells from SLE patients have already been more proliferated and differentiated than normal controls and produce much more Ig spontaneously in vitro culture than normal controls and these cells could be already refractory to further lL-6 stimulation in vitro. As other explanations, we expect that other lymophakines than IL-6 may contribute to the hypergammaglobulinemia in SLE patients.
